TY - JOUR TI - Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders AU - Bourbouli, M. AU - Rentzos, M. AU - Bougea, A. AU - Zouvelou, V. AU - Constantinides, V.C. AU - Zaganas, I. AU - Evdokimidis, I. AU - Kapaki, E. AU - Paraskevas, G.P. JO - Dementia and Geriatric Cognitive Disorders PY - 2017 VL - 44 TODO - 3-4 SP - 144-152 PB - S Karger AG SN - 1420-8008, 1421-9824 TODO - 10.1159/000478979 TODO - albumin; amino acid; amyloid beta protein; biological marker; glucose; phosphoprotein; TAR DNA binding protein; tau protein; threonine; amyloid beta protein; amyloid beta-protein (1-42); biological marker; DNA binding protein; peptide fragment; tau protein; TDP-43 protein, human; threonine, adult; amyotrophic lateral sclerosis; Article; blood brain barrier; cerebrospinal fluid; clinical assessment; clinical practice; controlled study; dementia assessment; diagnosis related group; diagnostic test accuracy study; diagnostic value; disease duration; educational status; enzyme linked immunosorbent assay; erythrocyte; female; frontal assessment battery; frontotemporal dementia; human; human cell; leukocyte; lumbar puncture; major clinical study; male; middle aged; Mini Mental State Examination; molecular diagnosis; post hoc analysis; priority journal; protein cerebrospinal fluid level; protein content; protein phosphorylation; receiver operating characteristic; sensitivity and specificity; aged; amyotrophic lateral sclerosis; frontotemporal dementia; genetics; metabolism; phosphorylation; Pick presenile dementia, Aged; Amyloid beta-Peptides; Amyotrophic Lateral Sclerosis; Biomarkers; DNA-Binding Proteins; Female; Frontotemporal Dementia; Humans; Male; Middle Aged; Peptide Fragments; Phosphorylation; Pick Disease of the Brain; tau Proteins; Threonine TODO - Background: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are nowadays recognized as spectrum disorders with a molecular link, the TAR DNA-binding protein 43 (TDP-43), rendering it a surrogate biomarker for these disorders. Methods: We measured cerebrospinal fluid (CSF) levels of TDP-43, beta-amyloid peptide with 42 amino acids (Aβ42), total tau protein (τT), and tau protein phosphorylated at threonine 181 (τP-181) in 32 patients with ALS, 51 patients with FTD, and 17 healthy controls. Double-sandwich commercial enzyme-linked immunosorbent assays were used for measurements. Results: Both ALS and FTD patients presented with higher TDP-43 and τT levels compared to the control group. The combination of biomarkers in the form of the TDP-43 × τT / τP-181 formula achieved the best discrimination between ALS or FTD and controls, with sensitivities and specificities >0.8. Conclusion: Combined analysis of TDP-43, τT, and τP-181 in CSF may be useful for the antemortem diagnosis of ALS and FTD. © 2017 S. Karger AG, Basel. ER -